Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AMRI signs license deal with Broad Institute
October 2016
SHARING OPTIONS:

ALBANY, N.Y.—In an effort to expand its services offerings, AMRI has inked a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard focused on the use of CRISPR-Cas9 gene-editing technology. Though no financial details were released, the terms of the license give AMRI access to IP related to CRISPR-Cas9 technology being used to enhance its drug discovery services offerings and associated client programs.
 
“While many people know CRISPR for its potential to edit defective genes to cure disease, there are a range of other applications in drug discovery for which CRISPR has significant utility that are critical to our customers’ R&D projects, notably drug target assessment and in-vitro model development for lead discovery and optimization,” said Christopher Conway, AMRI's senior vice president of Discovery and Development Services. “We are committed to continue to build our services offerings so that we stay in the leading position with important technologies such as CRISPR to enhance the success of our customers’ programs.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.